Table 4.

Multivariate risk of discontinuation of specific regimens vs EFV/FTC/TDF fixed-dose regimen (n = 1261, including n = 316 on EFV/FTC/TDF fixed-dose regimen).

Regimen	Hazard ratioa	p-value
LPV/r + AZT/3TC (n = 127)	2.33	< 0.001
LPV/r + TDF/FTC (n = 104)	2.03	< 0.001
EFV + AZT/3TC (n = 279)	1.83	< 0.001
ATV/r + TDF/FTC (n = 125)	1.19	0.217
EFV + TDF/FTCb (n = 310)	1.13	0.348

^aCovariates included in the Cox proportional hazards regression models were age, sex, region, Charlson Comorbidity Index score, substance use, and year of index date.

^bPatients who switched to EFV/FTC/TDF fixed-dose regimen were censored.

Abbreviations: ATV, atazanavir; AZT, zidovudine; EFV, efavirenz; FTC, emtricitabine; LPV, lopinavir; r, ritonavir; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine.